184 related articles for article (PubMed ID: 35804930)
1. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines.
Subtil FSB; Gröbner C; Recknagel N; Parplys AC; Kohl S; Arenz A; Eberle F; Dikomey E; Engenhart-Cabillic R; Schötz U
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804930
[TBL] [Abstract][Full Text] [Related]
2. Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining.
Schötz U; Balzer V; Brandt FW; Ziemann F; Subtil FSB; Rieckmann T; Köcher S; Engenhart-Cabillic R; Dikomey E; Wittig A; Arenz A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085396
[TBL] [Abstract][Full Text] [Related]
3. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
[TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma.
Huang JC; Cui ZF; Chen SM; Yang LJ; Lian HK; Liu B; Su ZH; Liu JS; Wang M; Hu ZB; Ouyang JY; Li QC; Lu H
Oncotarget; 2018 Feb; 9(12):10483-10496. PubMed ID: 29535821
[TBL] [Abstract][Full Text] [Related]
5. NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin.
Hsu CM; Lin PM; Tsai YT; Tsai MS; Tseng CH; Lin SF; Yang MY
Cell Death Discov; 2018; 4():57. PubMed ID: 29760955
[TBL] [Abstract][Full Text] [Related]
6. Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines.
Busch CJ; Becker B; Kriegs M; Gatzemeier F; Krüger K; Möckelmann N; Fritz G; Petersen C; Knecht R; Rothkamm K; Rieckmann T
Oncotarget; 2016 Jun; 7(24):35832-35842. PubMed ID: 27127883
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell.
Zhu H; Shi Y; Jiao X; Yang G; Wang R; Yuan Y
Oncol Lett; 2020 Dec; 20(6):326. PubMed ID: 33123242
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
Kim HJ; Gong MK; Yoon CY; Kang J; Yun M; Cho NH; Rha SY; Choi YD
Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.
Fokas E; Yoshimura M; Prevo R; Higgins G; Hackl W; Maira SM; Bernhard EJ; McKenna WG; Muschel RJ
Radiat Oncol; 2012 Mar; 7():48. PubMed ID: 22452803
[TBL] [Abstract][Full Text] [Related]
11. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses.
Mukherjee B; Tomimatsu N; Amancherla K; Camacho CV; Pichamoorthy N; Burma S
Neoplasia; 2012 Jan; 14(1):34-43. PubMed ID: 22355272
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cerniglia GJ; Karar J; Tyagi S; Christofidou-Solomidou M; Rengan R; Koumenis C; Maity A
Mol Pharmacol; 2012 Dec; 82(6):1230-40. PubMed ID: 22989521
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.
Kuger S; Graus D; Brendtke R; Günther N; Katzer A; Lutyj P; Polat B; Chatterjee M; Sukhorukov VL; Flentje M; Djuzenova CS
Transl Oncol; 2013 Apr; 6(2):169-79. PubMed ID: 23544169
[TBL] [Abstract][Full Text] [Related]
14. Impaired DNA double-strand break repair and effective radiosensitization of HPV-negative HNSCC cell lines through combined inhibition of PARP and Wee1.
Oetting A; Christiansen S; Gatzemeier F; Köcher S; Bußmann L; Böttcher A; Stölzel K; Hoffmann AS; Struve N; Kriegs M; Petersen C; Betz C; Rothkamm K; Zech HB; Rieckmann T
Clin Transl Radiat Oncol; 2023 Jul; 41():100630. PubMed ID: 37180052
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells.
Hintelmann K; Berenz T; Kriegs M; Christiansen S; Gatzemeier F; Struve N; Petersen C; Betz C; Rothkamm K; Oetting A; Rieckmann T
Front Oncol; 2021; 11():683688. PubMed ID: 34354944
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
18. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.
Yang F; Qian XJ; Qin W; Deng R; Wu XQ; Qin J; Feng GK; Zhu XF
PLoS One; 2013; 8(3):e59879. PubMed ID: 23533654
[TBL] [Abstract][Full Text] [Related]
19. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
Wang WJ; Long LM; Yang N; Zhang QQ; Ji WJ; Zhao JH; Qin ZH; Wang Z; Chen G; Liang ZQ
Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
